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Abstract 
Cattle are the main reservoir of Escherichia coli O157:H7, which is a foodborne pathogen that causes 
bloody diarrhea in adults and kidney damage in children . E. coli O157 is shed in the feces of cattle, which 
can be a contamination source of water, ground beef, fresh vegetables, and unpasterized milk and fruit 
juices. In 2003, shiga-toxin producing E. coli O157:H7 caused 73,000 illnesses, which resulted in over 
2,000 hospitalizations and 60 deaths in the United States. The estimated annual cost of this illness was 
$405 million, which included $370 million for premature deaths, $30 million for medical care, and $5 
million for lost productivity. Strategies to reduce this food borne illness must be further investigated. 
A new vaccine technology targeting E. coli O157:H7 in hopes of reducing the colonization of this 
pathogen in beef cattle has been developed (Epitopix, LLC, Wilmar, MN). This vaccine was designed to 
block the transport of iron into the bacterial cell, which is an essential nutrient needed for the survival of 
this microorganism. Previous trials showed that this vaccine elicited an immune response and reduced 
fecal shedding of the pathogen in five-month old Holstein steers. The purpose of this experiment was to 
further evaluate the efficacy of this new siderophore receptor/porin protein (SRP) technology by analyzing 
fecal shedding and immune responses of mixed-breed calves orally inoculated with E. coli O157:H7. 
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EFFECTS OF SRP VACCINE IN REDUCING E. COLI O157:H7 IN CATTLE 
 
A.B. Thornton1, D.U. Thomson1, J.T. Fox1, G.H. Loneragan2, 





 Cattle are the main reservoir of Es-
cherichia coli O157:H7, which is a food-
borne pathogen that causes bloody diar-
rhea in adults and kidney damage in chil-
dren .  E. coli O157 is shed in the feces of 
cattle, which can be a contamination 
source of water, ground beef, fresh vege-
tables, and unpasterized milk and fruit 
juices.  In 2003, shiga-toxin producing E. 
coli O157:H7 caused 73,000 illnesses, 
which resulted in over 2,000 hospitaliza-
tions and 60 deaths in the United States.  
The estimated annual cost of this illness 
was $405 million, which included $370 
million for premature deaths, $30 million 
for medical care, and $5 million for lost 
productivity. Strategies to reduce this food 
borne illness must be further investigated.     
 
 A new vaccine technology targeting E. 
coli O157:H7 in hopes of reducing the 
colonization of this pathogen in beef cattle 
has been developed (Epitopix, LLC, Wil-
mar, MN).  This vaccine was designed to 
block the transport of iron into the bacte-
rial cell, which is an essential nutrient 
needed for the survival of this microorgan-
ism.  Previous trials showed that this vac-
cine elicited an immune response and re-
duced fecal shedding of the pathogen in 
five-month old Holstein steers.  The pur-
pose of this experiment was to further 
evaluate the efficacy of this new 
siderophore receptor/porin protein (SRP) 
technology by analyzing fecal shedding 
and immune responses of mixed-breed 





 Thirty beef calves (3 to 4 months old) 
that were pre-tested and shown to be free 
of E. coli O157:H7, were processed and 
allowed to acclimatize as a herd at a local 
Manhattan, Kansas farm.  Calves were 
treated with One Shot Ultra 7, Bovi-Shield 
Gold 5, Micotil 300, and Dectomax. 
Calves were fed a starter ration at ap-
proximately 7 lbs per head per day and 
had ad libitum access to water and brome 
grass hay.   
 
 Approximately one month after arrival, 
calves were placed into one of two treat-
ment groups and administered either the 
SRP vaccine or the placebo on day 0 of the 
trial.  Twenty-one days after the first injec-
tion was administered, the calves were re-
vaccinated and transported to a BL-2 facil-
ity where they were confined to individual 
pens and allowed to acclimatize for one 
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week.  On day 36, calves from both treat-
ment groups were orally inoculated with a 
mixture of five strains of E. coli O157:H7, 
which were made resistant to nalidixic 
acid. 
 
 Cattle fecal samples and rectoanal mu-
cosal swab (RAMS) samples were col-
lected once a day for five consecutive days 
after oral challenge and then sampled three 
times a week for the following five weeks.  
Blood samples were collected on day 1, 
just prior to vaccination, and at weekly 
intervals to monitor antibody response to 
SRP vaccination in calves.  At the end of 
the study, calves were euthanized and 
samples were taken from the rumen, oma-
sum, abomasum, cecum, colon, and rec-
tum, along with tissue samples from the 
gall bladder mucosa and the rectoanal mu-
cosa, to determine the presence and con-
centration of E. coli O157:H7.  Detection 
of this microorganism was performed by 
transferring each sample to a selective en-
richment broth, by making serial 10-fold 
dilutions to allow for quantification of the 
microorganism, and by transferring each 
dilution to a selective agar containing 
nalidixic acid to simplify detection of the 
challenge organism.  Further antigenic 
testing was performed to confirm proper 
identification of the microorganism, and 
concentration of the bacteria from each 
sample was calculated. 
 
Results and Discussion 
 
 The presence and concentration of E. 
coli O157:H7 in the two treatment groups 
are illustrated in Figures 1-5.  From day 11 
to day 35 post challenge, there was a de-
crease (P<0.04) in fecal shedding of E. 
coli O157:H7 over time when the “SRP” 
treatment group was compared to the con-
trol group.  There was no significant dif-
ference between the two treatment groups 
when evaluating the concentration of the 
bacteria using the RAMS (rectoanal muco-
sal swab) sampling technique. There was a 
difference (P<0.05), however, when the 
prevalence in both the fecal and RAMS 
samples were combined (Figure 3), show-
ing that there were twice as many positive 
samples in the control group when com-
pared to the “SRP” treatment group by day 
32 post challenge.  
 
 The necropsy data also illustrated the 
efficacy of this vaccine showing the mean 
proportion of samples testing positive in 
the SRP treatment group were less 
(P<0.01) than those found positive in the 
non-vaccinate control group.  The SRP 
vaccinate group had higher (P<0.01) con-
centrations of anti SRP antibodies com-




 Overall, vaccination of calves with the 
SRP vaccine reduced the prevalence of E. 
coli O157:H7 in cattle.  This not only de-
fines a new potential strategy to reducing 
food borne illness, but also increases the 
































Figure 1  Average Percent of Animals Positive with NalR E. coli O157:H7 from Day 


























Figure 2   NalR E. coli O157:H7 Positive Cattle in Either the Fecal or Rectoanal  























Figure 3  Average Fecal Concentration of NalR E. coli O157:H7 in Cattle from the 
Day of Challenge to the Day of Necropsy 
 
 
























Figure 4  The Number of Animals from Each Treatment Group that had NalR E. 









































Figure 5  Calves’ Immunological Responses from the Day the First Vaccination was 
Administered to the Day of Challenge. 
 
 
